Background: We previously found 70 mg flat-dose docetaxel coadministered with ketoconazole to modulate CYP3A4 to be the maximum tolerated dose that resulted in comparable docetaxel area under the plasma concentration-time curve (AUC) as 75-100 mg/m 2 docetaxel.
introduction
Cytochrome P-450s (CYPs) are important drug-metabolizing enzymes susceptible to induction or inhibition by various drugs or herbs [1] . Such interactions can be exploited pharmacologically. For example, coadministration of ketoconazole, a potent, specific and reversible CYP3A4 inhibitor [2, 3] , caused threefold increase in the area under the plasma concentration-time curve (AUC) of cyclosporine, allowing 70%-80% reduction in cyclosporine dosage and 60% reduction in therapy costs [4] [5] [6] .
Docetaxel, a commonly used chemotherapeutic agent [7] , is extensively metabolized by hepatic and intestinal CYP3A isozymes, with CYP3A4 being the most active [8] . Significant interindividual variability in docetaxel pharmacology exists [9] [10] [11] . Several phase I studies that explored the coadministration of ketoconazole with docetaxel to inhibit CYP3A4 showed that ketoconazole reduced docetaxel clearance by 40%-50%, shifted influence of hepatic to renal function on docetaxel clearance but failed to reduce interindividual variability of docetaxel clearance [12] [13] [14] [15] . Two studies established a maximum tolerated dose (MTD) and schedule for ketoconazole-modulated docetaxel [12, 15] . One Western study on predominantly prostate cancer patients established MTD of docetaxel 55 mg/m 2 3-weekly coadministered with oral ketoconazole 400 mg twice daily (b.i.d.) continuously [12] . Our study on a range of solid tumors in Asians found ketoconazole to abrogate the influence of body surface area (BSA) and established MTD of 70 mg flat-dose docetaxel with ketoconazole 200 mg b.i.d. for 3 days [15] . At this dose, mean docetaxel AUC of 5.7 6 2.9 mg/lÁh was achieved, higher than the 4.8 mg/lÁh achieved in a cohort of 640 Caucasian patients treated with 75-100 mg/m 2 docetaxel [9] and the 3.8 6 2.2 mg/lÁh achieved in a cohort of 97 Asian breast cancer patients treated with 75 mg/m 2 docetaxel [16] . However, only a small number of patients (5 and 10, respectively) were treated at MTD in both studies and there are no published phase II studies to describe the tumor efficacy and toxicity profile of ketoconazole-modulated docetaxel. We conducted a phase II study of ketoconazole-modulated docetaxel in chemonaive breast cancer patients and compared docetaxel pharmacokinetics (PK) and pharmacodynamics (PD) between this and a similar population treated with conventional-dosed docetaxel. In addition, we genotyped pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factor-4a (HNF4a), which are orphan nuclear receptors that regulate transcription of multiple CYP enzymes including CYP3A [16] , as variants in these genes could influence CYP3A expression and activity and contribute to interindividual variability.
patients and methods
The study comprised a primary population of chemonaive locally advanced/metastatic breast cancer patients treated with 70 mg flat-dose docetaxel modulated by ketoconazole and a comparison population treated with conventional-dosed docetaxel 75 mg/m 2 , recruited into two sequential protocols that were approved by the institution's ethics review board. Eligibility criteria were similar for the two cohorts and included female patients aged ‡18 years with histologically or cytologically confirmed locally advanced or metastatic breast cancer, measurable primary tumor with both diameters ‡2.0 cm, no prior chemotherapy or hormonal therapy for breast cancer, Karnofsky performance score ‡70, estimated life expectancy ‡12 weeks, absolute neutrophil count (ANC) ‡ 1.5 · 10 9 /l, platelets ‡ 100 · 10 9 /l, total bilirubin £ 1.5· upper limit of normal (ULN), alanine transaminase/aspartate transaminase (ALT/AST) £ 2.5 · ULN or £ 5· for patients with liver metastases, creatinine £ 1.5 · ULN, left ventricular ejection fraction ‡50%, signed informed consent, and if applicable a negative pregnancy test £7 days before study enrollment.
Exclusion criteria included prior or concurrent treatment of breast cancer, treatment with any investigational drug within 30 days, pregnancy, breast-feeding, poorly controlled diabetes mellitus, symptomatic brain metastases, Clinical Toxicity Criteria (CTC) of grade 2 or more peripheral neuropathy, significant history of neurological or mental disorder, and hypersensitivity to Tween 80, the vehicle for docetaxel.
treatment plan
The primary population was treated with four cycles of 3-weekly preoperative ketoconazole-modulated docetaxel, followed by surgery to remove the primary tumor, and four cycles of postoperative 3-weekly doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 (AC). Docetaxel was administered at 70 mg flat dose i.v. over 1 h. Oral ketoconazole was administered at 200 mg b.i.d. for six doses, starting 2 days before docetaxel administration. To ensure absorption, ketoconazole was administered with at least 100 ml cola or orange juice. Patients in the conventional-dosed cohort were treated with six cycles of alternating sequential docetaxel (T) and doxorubicin (A) every 3 weeks, surgery, followed by two more cycles of alternating docetaxel and doxorubicin (T / A / T / A / T / A / surgery / T / A). Doxorubicin was administered at 75 mg/m 2 as a slow bolus and docetaxel at 75 mg/m 2 over 1 h.
All patients received premedication with oral dexamethasone 8 mg b.i.d. for 3 days, starting 1 day before each docetaxel infusion. For the first cycle, i.v. premedications including antiemetics were standardized to dexamethasone 20 mg and ondansetron 8 mg to reduce potential confounders for docetaxel PK analysis. Antiemetics for subsequent cycles could be modified at the investigator's discretion. Primary prophylaxis with colony-stimulating factors was not allowed. ANC ‡ 1.5 · 10 9 /l and platelets ‡ 100 · 10 9 /l were required before the start of each new cycle. There was no dose reduction for ketoconazole. Docetaxel dose was reduced by 20% for grade 3-4 neutropenia with documented infection or fever, platelets < 25 · 10 9 /l or platelets < 50 · 10 9 /l associated with bleeding. In the event of grade 2 peripheral neuropathy, grade 2 myalgia, asthenia or fatigue >7 days, docetaxel doses were reduced by 20%. Up to two dose reductions were allowed. If serum bilirubin was elevated to >1.5 · ULN or AST/ALT to >2.5 · ULN or >5 · ULN in patients with or without liver metastases, respectively, the next cycle would be delayed until recovery to below these levels. Treatment could be delayed up to 42 days to allow for recovery from toxic effects. In the event of grade 3-4 liver toxicity, peripheral neuropathy or hypersensitivity, docetaxel would be discontinued permanently.
tumor evaluations
For both study populations, baseline evaluations included medical history and physical examination, caliper measurement of clinically palpable tumor lesions, hematology and biochemistry and radiological assessment including plain chest X-ray and other imaging studies at the investigator's discretion. Clinical assessment was repeated every 3 weeks, while radiological assessments were repeated every 6 weeks as appropriate. Bidimensional tumor measurements were carried out and responses classified according to the World Health Organization criteria [17] . Adverse reactions were graded according to the National Cancer Institute-CTC version 2.0.
surgery
Patients underwent lumpectomy or mastectomy for curative intent in nonmetastatic patients and for local control in metastatic patients after completing preoperative chemotherapy. If patients in the ketoconazolemodulated cohort were deemed ineligible for resection after four cycles of docetaxel, four cycles of AC would be given before surgery. Any disease progression would be cause for early discontinuation of docetaxel and switch to AC before surgery.
PK analysis
Blood samples were taken for docetaxel PK analyses during the first docetaxel cycle in both studies, at 0, 30 and 60 min and 2, 5, 7 and 24 h from the start of infusion. Docetaxel concentrations were analyzed with liquid-liquid extraction and reversed-phase high-performance liquid chromatography [18] . Docetaxel clearance was estimated using the standard two-compartmental method with the WINNONLIN software [15] . Midazolam phenotyping test was not carried out as midazolam clearance did not correlate well with docetaxel clearance in our phase I study [15] .
genotyping of orphan nuclear receptor genetic variants
Ten milliliters whole blood was collected from each subject, and genomic DNA extracted and genotyped for four previously described variants, HNF4aMet49Val, HNF4aThr130Ile, CARPro180Pro and PXR-24381A>C with PCR amplification followed by automated sequencing [16] .
comparison of docetaxel PK/PD between ketoconazolemodulated and conventional-dosed population during cycle 1 docetaxel Docetaxel PK parameters evaluated were clearance, AUC, half-life, maximum plasma concentration (C max ) and volume of distribution; PD parameters evaluated were total white count, ANC, hemoglobin and platelets on days 8, 15 and nadir and grade 3-4 non-hematologic toxic original article Annals of Oncology effects. For comparison of cycle 1 tumor response, patients who achieved ‡25% reduction in tumor dimension after the first treatment cycle were arbitrarily defined as responders.
data analysis
Pearson's correlation was used to determine the correlation between docetaxel clearance and clinical predictors that were continuous variables. Linear regression was used in multivariate analysis for docetaxel clearance. Chi-square test and t-test or the corresponding nonparametric tests were used to test various categorical and continuous clinical variables. P value of <0.05 was considered statistically significant. As four genetic variants were evaluated in pharmacogenetic analysis, P value of <0.0125 was considered statistically significant after correcting for multiple testing. Statistical calculations were computed using SPSS Version 13.0 (SPSS Inc., Chicago, IL).
results patient characteristics
The ketoconazole-modulated cohort included 31 patients enrolled from July 2005 to September 2006 ( Table 1 ). The conventional-dosed cohort included 51 patients enrolled from April 2002 to July 2005. The majority of patients in both studies were Chinese or Malay. All except one subject had clinical T3 or T4 disease; $70% of subjects had nonmetastatic disease in both studies and were treated with curative intent. There were no significant differences in demographic characteristics, tumor features and organ function between the two populations, with the exception of proportion of clinical T4 disease and serum albumin, which were greater and lower, respectively, in the conventional-dosed population.
docetaxel PK Docetaxel AUC was not significantly different between the ketoconazole-modulated and conventional-dosed cohorts (3.93 6 2.77 versus 3.77 6 2.70 mg/lÁh, P = 0.794) ( Table 2 ; Figure 1a ). Docetaxel clearance was $40% lower in the ketoconazole-modulated cohort (22.05 6 8.29 versus 36.52 6 13.39 l/h, P < 0.001), half-life was longer, while C max was lower although the differences were not statistically significant. There was no significant difference in docetaxel volume of distribution between the two cohorts. Coefficient of variance was 70% versus 72% for docetaxel AUC and 38% versus 37% for docetaxel clearance for ketoconazole-modulated versus conventional-dosed docetaxel, respectively.
hematologic and non-hematologic toxic effects
After one docetaxel cycle, patients treated with ketoconazolemodulated docetaxel had significantly higher day 8 and nadir Table 1 . Demographic and tumor characteristics of ketoconazole-modulated and conventional-dosed cohorts ANC compared with conventional-dosed docetaxel and were less likely to experience grade 4 neutropenia and febrile neutropenia (Table 2) . When all four cycles of docetaxel were considered for the ketoconazole-modulated cohort, the main dose-limiting toxic effects were febrile neutropenia (n = 4, 12.9%) and grade 3 diarrhea (n = 1, 3%). No other grade 3 non-hematologic toxic effects were experienced. The most common grade 1 and 2 non-hematologic toxic effects were fatigue (77.4% and 3.2%), diarrhea (48.4% and 9.7%), vomiting, (25.8% and 3.2%), myalgia (35.5% and 0%), peripheral neuropathy (6.5% and 0%), and hypersensitivity reaction (9.7% and 3.2%).
tumor response
After one docetaxel cycle, 52% of the patients in the ketoconazole-modulated cohort and 55% of the patients in the conventional-dosed cohort achieved ‡25% reduction in tumor dimensions (P = 0.772). Results were similar when the analysis was carried out after stratifying for T-and N-stage. The clinical complete response (cCR) and clinical partial response (cPR) rates to four cycles of ketoconazole-modulated docetaxel were 9.7% and 54.8%, respectively, with overall objective response rate (ORR) being 64.5%; 32.3% and 3.2% of patients, respectively, had stable disease and progressive disease. In comparison, 4.1% and 77.6% achieved cCR and cPR, respectively, to six cycles of alternating docetaxel and doxorubicin, resulting in 81.7% ORR. The stable disease and progressive disease rates were 16.3% and 2.0%, respectively.
In the ketoconazole-modulated cohort, seven patients (23%) had inadequate clinical response to docetaxel and received preoperative AC, including one patient with progressive disease after two docetaxel cycles, four patients with stable disease and two patients with partial response (PR) after four docetaxel cycles but who remained ineligible for resection. Thirty of 31 patients (97%) underwent surgery and none achieved complete pathologically documented response (pathological response; pCR). For the conventional-dosed cohort that received six cycles of alternating doxorubicin and docetaxel, 38 of 51 (75%) underwent surgery and four patients achieved pCR (11% of operated population, 8% of entire cohort).
correlation between docetaxel PK and PD in the ketoconazole-modulated cohort
In the ketoconazole-modulated cohort, patients who developed grade 4 neutropenia at cycle 1 (n = 10) had significantly higher docetaxel AUC (5.33 6 4.4 versus 3.27 6 1.16 mg/lÁh, P = 0.05) and numerically lower docetaxel clearance (18.34 6 8.71 versus 23.81 6 7.67 l/h, P = 0.086) compared with those who did not (Table 3) . Patients who developed febrile neutropenia (n = 4) had higher docetaxel AUC (Table 3) , ketoconazolemodulated docetaxel clearance significantly correlated with creatinine clearance (CrCl), alpha-1 acid glycoprotein (AAG) and BSA. BSA and CrCl demonstrated colinearity (r = 0.703, P < 0.001). Multiple linear regression analysis selected BSA and AAG in the final model: docetaxel clearance = [26.404 + 22.12 · (BSA) 2 6.36 · (AAG)] (overall r = 0.600, P = 0.002).
interethnic differences in CYP3A4 inhibition by ketoconazole on docetaxel PK/PD Interethnic differences in docetaxel PK/PD were observed with ketoconazole-modulated docetaxel (Figure 1b-e) . Chinese had the lowest docetaxel clearance and highest docetaxel AUC, followed by Malays and Indians [clearance 18.6 6 5.7, 23.7 6 9.3, 30.6 6 6.7 l/h, respectively, P = 0.048; P = 0.017 on Jonckheree-Terpstra (JT) trend test; AUC 4.2 6 1.4, 4.1 6 3.9, 2.4 6 0.5 mg/lÁh, respectively, P = 0.048; P = 0.017 JT trend test]. There were no statistically significant differences in BSA between the races (1.53 6 0.15, 1.58 6 0.18, 1.68 6 0.23 m 2 , respectively, P = 0.495; P = 0.264 JT trend test). In concordance, Chinese experienced more neutropenia, followed by Malays and Indians, from ketoconazole-modulated docetaxel (day 8 ANC 0.8 6 0.8, 1.5 6 1.1, 1.7 6 1.1 · 10 9 /l, respectively, P = 0.046, P = 0.013 JT trend test; grade 4 neutropenia 57%, 14%, 0%, respectively, P = 0.024).
In contrast, no significant differences in docetaxel PK or neutropenia between the races were observed for unmodulated 75 mg/m 2 docetaxel (clearance 37.2 6 15.0, 35.2 6 11.6, 38.2 6 6.7 l/h, respectively, P = 0.648; AUC 3.9 6 3.4, 3.6 6 0.9, 3.0 6 0.9 mg/lÁh, respectively, P = 0.563; day 8 ANC 0.47 6 0.69, 0.48 6 0.26, 0.43 6 0.42 · 10 9 /l, respectively, P = 0.248; grade 4 neutropenia 77%, 57%, 75%, respectively, P = 0.373).
No significant interethnic differences in serum AAG were observed in the ketoconazole-modulated (P = 0.084) and conventional-dosed (P = 0.097) cohorts. The four orphan nuclear receptor genetic variants have been previously reported in the conventional-dosed docetaxel cohort [16] ; none correlated with docetaxel clearance, AUC or cycle 1 neutropenia. In the ketoconazole-modulated cohort, patients who were homozygous wild type for HNF4aMet49Val(A > G) had lower cycle 1 day 8 ANC (0.62 6 0.77 versus 1.45 6 1.02 · 10 9 /l, AA versus AG/GG, P = 0.011) and more grade 4 neutropenia (75% versus 17%, AA versus AG/GG, P = 0.003) compared with those with at least one variant allele. Interethnic differences in genotype frequencies of HNF4aMet49Val were observed, with more Chinese being homozygous wild type compared with Malays and Indians (50% versus 7% versus 0%, P = 0.02). No correlation was observed between HNF4aMet49Val and docetaxel clearance or AUC. There was also no correlation between the other three genetic variants and docetaxel PK/PD.
discussion
We describe the first phase II study of ketoconazole-modulated docetaxel along with the first systematic comparison of docetaxel PK/PD with or without ketoconazole modulation. We affirmed our phase I finding that ketoconazole modulation reduced docetaxel clearance by 40% and that 70 mg flat-dose docetaxel coadministered with ketoconazole achieved equivalent docetaxel AUC as unmodulated conventional-dosed docetaxel [15] . Docetaxel half-life was prolonged, while the maximum plasma concentration was reduced, resulting in neutrophil suppression that was less steep but recovered more slowly compared with conventional dosing. This change was clinically significant as it translated into lower incidence of febrile neutropenia (3.2% versus 23.5%). Non-hematologic toxic effects and tumor efficacy were similar, confirming ketoconazole inhibition of CYP3A4 to be feasible in reducing docetaxel requirements while maintaining drug levels and tumor efficacy, with the added advantage of improved safety.
The 'conventional-dosed' cohort was treated with 75 mg/m 2 docetaxel in our study, rather than the approved first-line dose of 100 mg/m 2 in Caucasians [19] . This is a common starting dose among Asians that results in similar AUC as 100 mg/m 2 docetaxel in Caucasians [11] and is significantly myelosuppressive with reported grade 3-4 neutropenia rates between 82% and 90% and febrile neutropenia rates of up to 41% [16, 20, 21] . In Japan, the approved starting dose is 60 mg/m 2 [22, 23] , highlighting intergeographic differences in docetaxel tolerance. Consistent with previous studies [13, 15] , we found that ketoconazole inhibition of CYP3A4 failed to reduce variability in docetaxel PK/PD, indicating interindividual variability to ketoconazole inhibition, an interesting observation that warrants further evaluation to better appreciate the clinical impact of drug interactions. Consistent with previous reports, ketoconazole modulation abrogated the influence of hepatic function on docetaxel clearance. CrCl, AAG and BSA were major predictors of ketoconazole-modulated docetaxel clearance and may be incorporated clinically to further refine the regimen. Although patients in the ketoconazole-modulated cohort had higher serum albumin levels, it was not a predictor of docetaxel clearance; there was also no significant difference in the levels of AAG, a known predictor of docetaxel clearance, between the two treatment cohorts. As such, neither factor is expected to contribute to the altered docetaxel PK/PD observed with ketoconazole modulation.
Ketoconazole is known to inhibit C17-C20 lyase involved in androgen biosynthesis. In a study in postmenopausal breast cancers, high-dose ketoconazole at 400 mg three times a day continuously resulted in small suppression of estradiol concentrations but no effects on estrone levels; only 1 of 14 patients had PR. In our study, ketoconazole 200 mg b.i.d. was administered for only 3 days every 3 weeks for four cycles. This short-duration low-dose ketoconazole regimen is not expected to have significant tumor efficacy [24] , and we believe the docetaxel PK/PD effects observed in our study were predominantly due to CYP3A4 modulation.
Interethnic differences in docetaxel PK/PD were found in the ketoconazole-modulated cohort, with Chinese having the lowest docetaxel clearance, highest AUC, lowest day 8 neutrophil count and highest grade 4 neutropenia rate. This was followed by Malays and then Indians. Similar interethnic differences were not observed with conventional dosing, indicating that interethnic differences in CYP3A inhibition by ketoconazole exist and should be considered when evaluating [25] . The variant may thus interfere with HNF4a function and influence the expression of genes involved in cell growth, immune function and amino acid, lipid and steroid metabolism, some of which may in turn influence the degree of docetaxel-induced myelosuppression. In addition, other genetic factors or dietary and cultural differences between the races may account for these interesting differences and warrant further evaluation. This is the first systematic comparison of docetaxel PK/PD with or without ketoconazole modulation in a fairly large sample set of breast cancer patients. Although the two cohorts were not enrolled into a single prospective comparison study, they were recruited into sequential studies in a single institution applying similar eligibility criteria. Demographic and tumor characteristics of the two cohorts were similar; chemonaive patients with good performance and organ function were enrolled; collection of plasma samples and clinical parameters for PK/PD analysis was standardized, reducing potential confounders. In addition, CYP3A4 modulation was achieved with short-course ketoconazole which is convenient and safe. One major limitation is that the conventional-dosed cohort received alternating sequential docetaxel and doxorubicin, making comparison of overall clinical and pathological response rates unreliable. However, the 64.5% ORR achieved by four cycles of ketoconazole-modulated docetaxel is similar to the reported 55% ORR with 75-100 mg/m 2 docetaxel in first-line metastatic breast cancers [26] and 49%-68% ORR with four to six cycles of neoadjuvant docetaxel at 100 mg/m 2 [27, 28] , indicating that ketoconazole-modulated docetaxel is not inferior to conventional treatment. The pCR rates were expectedly low in both cohorts in this study as most patients had locally advanced tumors and one-third had metastatic disease.
conclusions Ketoconazole-modulated docetaxel resulted in similar drug levels, tumor efficacy, non-hematologic toxic effects, but less febrile neutropenia compared with conventional dosing, and is a feasible and safe alternative in advanced cancers. Interethnic differences in CYP3A inhibition by ketoconazole exist and are important when evaluating the impact of concomitant medications that inhibit CYP3A4. 
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